R

ise and shine, everyone, another busy day is on the way. The Pharmalot campus, for instance, is already bustling as our short person has darted out the door for the local schoolhouse and the official mascots are hungrily sniffing about the grounds for wild game. As for us, the coffee kettle is fired up so we can brew delicious cups of stimulation. So time to dig into the tidbits below and get your game going. Have a wonderful day and do keep in touch …

The Food and Drug Administration approved a three-in-one lung inhaler from GlaxoSmithKline (GSK) for treating chronic lung disease, Reuters tells us. Trelegy Ellipta, which is the first such treatment for chronic obstructive pulmonary disease, is a key new product for the drug maker, which is scrambling to keep its lead in respiratory medicines despite falling sales of its older Advair drug.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X